OBJECTIVE:To screen the optimal regimen of acupuncture and moxibustion for obstructive sleep apnea hypopnea syndrome (OSAHS), so as to provide the evidences for clinical decision-making. METHODS:From 7 databases in Chinese and English i.e. the Full-Text Database of China Journal Network (CNKI), Wanfang Data Knowledge Service Platform (Wanfang), VIP Information Chinese Journal Service Platform (VIP), Chinese Biomedical Literature Database (SinoMed), PubMed, Web of Science (WOS) and Cochrane Library, randomized controlled trial (RCT) articals of OSAHS treated with acupuncture and moxibustion were searched. The quality of evidence was evaluated with the modified Jadad scale, the evaluation index was established and the optimal regimen of acupuncture and moxibustion for OSAHS was screened by multi-index decision analysis. RESULTS:A total of 10 RCTs were included, and the filiform needling therapy was optimal in treatment of OSAHS. The acupoints included Lianquan (CV23), Danzhong (CV17), Zhongwan (CV12), and bilateral Kongzui (LU6), Pishu (BL20), Fenglong (ST40), Zusanli (ST36), Yinlingquan (SP9) and Zhaohai (KI6). Zusanli (ST36) received the reinforcing method, Pishu (BL20) and Fenglong (ST40) were stimulated with the reducing technique, and the rest acupoints with the uniform reinforcing-reducing. Each acupoint was manually manipulated once every 10 min during the needle retention for 30 min. Acupuncture was delivered once a day, 5 times a week and for consecutive 4 weeks. Among the included literature, the severity of disease was not reported in detail, the filiform needling was the dominant intervention, the local acupoints such as Lianquan (CV23) and Panglianquan (Extra) were mainly selected. The apnea-hypopnea index and the minimum oxygen saturation were taken as the evaluation indexes, and the effect was evaluated in reference to the generally accepted standards. The attention to safety evaluation was insufficient, the report on methodology was not adequate and the quality was low. CONCLUSION:Filiform needling is the dominant therapy of acupuncture and moxibustion for OSAHS, and the local acupoints are considered specially. But the quality of clinical research should be improved.

Background:Upper extremity pain disorder and motor impairment (UE-PDMI) in patients with stage I post-stroke shoulder-hand syndrome (SHS) is a common neurological comorbidity. Current interventions are with effect limitations or side effects. Moxibustion is utilized as an integrative treatment for UE-PDMI. A novel meta-analysis should be performed due to the increasing number of relevant randomized controlled trials published recently. This study aims to evaluate the efficacy and safety of moxibustion treatment for UE-PDMI. Methods:Eight databases, including the Cochrane Library, Embase, PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), SinoMed database, China Science and Technology Journal Database (VIP) and WanFang database, were systematically searched, from their inception through May 15 2024, to identify potentially relevant randomized controlled trials (RCTs) on moxibustion for UE-PDMI in SHS patients. The data from the eligible RCTs was extracted by two independent investigators. The RevMan software (version 5.4.1) was employed for conducting the meta-analysis. The online GRADEpro tool was applied for rating the quality of evidence. Results:A total of 32 RCTs, involving 2,814 patients with UE-PDMI, were included. The favorable results were considered to be reflected by reduced scores on a visual analog scale (VAS) (mean difference [MD] = -1.68, 95% CI - 2.08, -1.28, p < 0.05), improved scores on the Fugl-Meyer Assessment of the Upper Extremity (FMA-UE, MD = 8.76, 95% CI: 7.00, 10.53, p < 0.05), higher scores on the modified Barthel index (MBI, MD = 10.27, 95% CI: 6.16, 14.34, p < 0.05) or Barthel index (BI, MD = 8.06, 95% CI: 6.20, 9.91, p < 0.05), and lower scores for functional impairment on National Institute of Health Stroke Scale (NIHSS, MD = -2.34, 95% CI: -2.96, -1.72, p < 0.05) when moxibustion was combined with rehabilitation training (RT), in contrast to control groups that implemented RT alone. The better total effective rates (TERs) were achieved when moxibustion was combined with RT (risk ratio [RR] = 1.27, 95% confidence interval [CI]:1.21, 1.33, p < 0.05) or with western medicine (RR = 1.18, 95% CI: 1.02, 1.35, p = 0.02) in comparisons to corresponding control groups. There was no significant difference in the occurrence of adverse events (AEs) between corresponding experimental and control groups (RR = 1.62, 95% CI: 0.63, 4.16, p > 0.05). Conclusion:This study demonstrates that moxibustion as an adjuvant therapy may play a positive role in relieving pain and improving upper extremity motor function for patients with stage I SHS, given its convenience in generating prolonged effects in communities. However, a larger number of rigorously designed, pre-registered RCTs are highly needed to verify its clinical efficacy with a higher level of certainty. Systematic review registration:https://www.crd.york.ac.uk/prospero/, identifier [CRD42024601605].

This study aimed to assess the therapeutic efficacy of moxibustion assisted therapy in combination with Qishen Tongmai Yin No. 1 on arteriosclerosis obliterans (ASO) patients. The impact on clinical symptoms, sign scores, foot dorsum temperature, foot dorsum artery blood flow, and overall clinical efficacy were analyzed. Sixty-three ASO patients from Beijing Xiaotangshan Hospital and Beijing Shijitan Hospital (January 2020-December 2021) were divided into 3 groups: a Qi Shen Tong Mai Yin I-only group, a moxibustion-only group, and a combined treatment group receiving both moxibustion and Qi Shen Tong Mai Yin No. 1. The treatment group took Qi Shen Tong Mai Yin No. 1 orally 3 times daily for 1 month. Moxibustion, employing a mild method, was applied once daily for 35 minutes over a month. Key acupoints included bilateral kidney Shu, Guan Yuan, Ming Men, Zu San Li, Wei Zhong, San Yin Jiao, and Yao Yang Guan. Posttreatment, clinical symptom scores, and dorsum foot parameters were measured, including foot temperature and dorsum foot artery blood flow. Total effective and cure rates were calculated. Pretreatment, no significant differences existed among the 3 groups (P > .05). Posttreatment, the clinical efficacy, dorsalis pedis temperature, dorsalis pedis artery blood flow, and symptom scores significantly improved in all groups (P < .05). Differences in these indicators were also significant among the 3 groups (P < .05). Moxibustion assisted therapy combined with Qishen Tongmai Yin No. 1 enhances total effective and cure rates in ASO patients, improving foot temperature, blood flow, microcirculation, and overall clinical efficacy. Additionally, this combination reduces scores for intermittent claudication, pain, skin temperature, soreness, skin color, and numbness, mitigating disease progression. Safety evaluation indicated no adverse events during treatment, demonstrating the safety of the combined therapy.

To analyze the research hotspots,frontiers and trends of fire needle clinical randomized controlled trial(RCT)literature in the past 10 years by using bibliometrics and knowledge mapping methods.Six Chinese and English databases including CNKI,Wanfang,VIP,SinoMed,PubMed and Web of Science(WOS)were searched for RCT research literature on fire needle.CiteSpace V6.1.R6 and VOSviewer V1.6.18 software were used to analyze the cooperation network,keyword co-occurrence,keyword clustering,keyword timeline,keyword emergence,etc.,and to draw a visual knowledge map.A total of 1 973 Chinese articles and 3 English articles were included.The top three institutions that publish articles were Guangzhou University of CM,Heilongjiang University of CM and Beijing Hospital of TCM Affiliated to Capital Medical University.The fire needle was often combined with acupuncture,cupping and bloodletting therapy in the treatment of acne,vitiligo,lumbar disc herniation,herpes zoster,stroke sequelae,facial paralysis,knee osteoarthritis and so on.The research frontiers included the combined application of fire needle and other therapies,clinical mechanism research and efficacy evaluation index research.In the future,we should expand the dominant diseases,optimize the research design,strengthen the cooperation between the teams,and carry out high-level clinical research.

BackgroundThe activation of YAP/TAZ transcriptional co-activators, downstream effectors of the Hippo/YAP pathway, is commonly observed in human cancers, promoting tumor growth and invasion. The aim of this study was to use machine learning models and molecular map based on the Hippo/YAP pathway to explore the prognosis, immune microenvironment and therapeutic regimen of patients with lower grade glioma (LGG).MethodsSW1783 and SW1088 cell lines were used as in vitro models for LGG, and the cell viability of the XMU-MP-1 (a small molecule inhibitor of the Hippo signaling pathway) treated group was evaluated using a Cell Counting Kit-8 (CCK-8). Univariate Cox analysis on 19 Hippo/YAP pathway related genes (HPRGs) was performed to identify 16 HPRGs that exhibited significant prognostic value in meta cohort. Consensus clustering algorithm was used to classify the meta cohort into three molecular subtypes associated with Hippo/YAP Pathway activation profiles. The Hippo/YAP pathway’s potential for guiding therapeutic interventions was also investigated by evaluating the efficacy of small molecule inhibitors. Finally, a composite machine learning models was used to predict individual patients’ survival risk profiles and the Hippo/YAP pathway status.ResultsThe findings showed that XMU-MP-1 significantly enhanced the proliferation of LGG cells. Different Hippo/YAP Pathway activation profiles were associated with different prognostic and clinical features. The immune scores of subtype B were dominated by MDSC and Treg cells, which are known to have immunosuppressive effects. Gene Set Variation Analysis (GSVA) indicated that subtypes B with a poor prognosis exhibited decreased propanoate metabolic activity and suppressed Hippo pathway signaling. Subtype B had the lowest IC50 value, indicating sensitivity to drugs that target the Hippo/YAP pathway. Finally, the random forest tree model predicted the Hippo/YAP pathway status in patients with different survival risk profiles.ConclusionsThis study demonstrates the significance of the Hippo/YAP pathway in predicting the prognosis of patients with LGG. The different Hippo/YAP Pathway activation profiles associated with different prognostic and clinical features suggest the potential for personalized treatments.

Background:Post-stroke shoulder-hand syndrome (PS-SHS), a common neurological comorbidity after stroke episodes, poses a grave threat on patients' functional recovery. Preliminary trials have demonstrated that the acupuncture and moxibustion treatment, including a dermal acupuncture tapping method known as plum blossom needling (PBN) can improve pain and motor dysfunctions in patients with PS-SHS. However, there are few reports describing simultaneous moxibustion treatment in combination with PBN. Hence, a novel plum blossom needle device with mild moxibustion (PBNMM) was developed to evaluate its potential efficacy and safety in patients with stage 1 PS-SHS.Materials and Methods:This multicenter, sham-controlled, randomized controlled trial (RCT) will recruit 102 eligible patients with stage 1 PS-SHS from three clinical centers, randomly allocated in a ratio of 1:1:1 to the PBNMM group, PBNMM with no moxa smoke (PBNMM-NMS) group and sham control group. Patients in each group will receive a 30-minute treatment once per day for 4 weeks, with 5 consecutive sessions per week, for a total of 20 sessions. The primary outcome measure will be defined as the decreased scores from baseline in the visual analog scale (VAS) assessment at week 4. Secondary outcome measures will include scores on the Fugl-Meyer Assessment of the Upper Extremity Scale (FMA-UE), the Modified Barthel Index (MBI), and the somatosensory evoked potential (SEP) records. All outcomes will be evaluated at baseline and weeks 4, 5, 6 and 10, and the intention-to-treat analysis will be applied.Conclusion:This study aims to provide robust evidence for the efficacy and safety of the PBNMM for PS-SHS treatment, as well as the specific impact of moxibustion smoke itself in dealing with PS-SHS.Clinical Trial Registration:Chinese Clinical Trial Registry No. ChiCTR2200062441. Registered on 7 August 2022.

手功能障碍是中风后常见并发症之一,因手功能的活动极为精密,投射在大脑皮质区域广泛,一旦受损其功能的恢复极为困难,严重影响患者的生活和工作质量.首都国医名师贺普仁教授认为中风手功能障碍多与寒凝脉阻、气血瘀滞、经筋失荣相关,而火针因其有针有热,集中了针刺与艾灸双重优势,可借助针力与火力,无邪则温补,有邪则祛邪,可温通筋脉,使经络通畅、气血调和,又可通过借火助阳鼓舞血气运行,散结开滞,疏导气血.本文通过介绍贺氏火针治疗中风后手功能障碍,以期对其临床治疗提供新思路.

髋关节撞击综合征是导致髋关节疼痛的常见原因,也是导致髋关节骨性关节炎的重要致病因素.由于股骨头与髋臼结构异常,在运动中容易发生碰撞,导致髋臼周围软组织损伤,从而引起关节受限、疼痛和功能障碍,进而影响日常生活活动.近些年随着微创手术的发展,髋关节镜手术逐渐成为髋关节撞击综合征主要的手术治疗方法,不仅可以在术中对患者进行动态评估,还可以直接解除异常的解剖结构.患者术后常面临着疼痛、肌力减退以及其他合并症等问题,所以关节镜术后功能障碍的康复也越来越受到人们的关注和重视,成为髋关节撞击综合征术后功能恢复的重要手段.本文通过归纳总结近五年国内外髋关节撞击综合征关节镜术后康复治疗的最新研究成果,旨在为该病术后的临床康复提供新的诊疗思路和依据.

目的 观察贺氏火针对中风软瘫期手功能障碍的临床疗效.方法 收集2019年1月至2022年12月期间北京小汤山医院脑梗死患者60例,随机分为对照组和试验组,每组30例.试验组予以常规康复结合贺氏火针治疗,对照组仅予常规康复治疗,观察两组患者徒手肌力检查、改良Ashworth评分(MAS)、偏瘫手功能评分的变化.结果 治疗后试验组患者徒手肌力、改良Ashworth评分(MAS)、偏瘫手功能评分结果明显优于对照组,差异具有统计学意义(P＜0.01,P＜0.05);试验组患者徒手肌力检查、改良Ashworth评分(MAS)、偏瘫手功能评价治疗前后变化值均高于对照组,差异均具有统计学意义(P＜0.01).结论 贺氏火针在中风软瘫期应用可以增加患者肌力、诱发肌张力,促进手功能障碍的恢复.

Abstract Background Obstructive sleep apnea hypopnea syndrome (OSAHS) is considered to be greatly harmful due to its high incidence and low awareness rate, and has a considerable adverse impact on quality of life (QoL) for patients and their cohabitants. Our previous pilot trial suggested that fire needle might be a potential treatment option for OSAHS. We will conduct this trial to assess the efficacy and safety of fire needle for the moderate OSAHS. Methods/design A total of 102 eligible patients will be randomly allocated to either the fire needle group or the sham acupuncture group. Each patient will receive 16 sessions over eight weeks. The primary outcome is apnea hypopnea index (AHI). Secondary outcomes includes oxygen desaturation index (ODI)and other polysomnography (PSG) monitoring indicators, scores of Pittsburgh sleep quality index (PSQI) questionnaires, scores of Epworth sleepiness (ESS) scale questionnaires and visual analogue scores (VAS) of the patient's snoring by cohabitants. All patients who receive randomization will be included in the intent-to-treat analysis. Discussion The finding of this trial will provide high-quality evidence on the efficacy of fire needle for treating moderate OSAHS. According to the result, we will establish a fire needle treatment scheme for moderate OSAHS. Results of this research will be published in peer-reviewed journals. Trial registration: Chinese Clinical Trail Registry, ChiCTR2300067509. Registered on 10 Jan 2023.

卒中后抑郁(post-stroke depression,PSD)严重阻碍了卒中患者康复.王居易教授主张针灸临床应以"经络辨证"为纲,根据六经气化不同特性,从"开阖枢"与六经气血的内在联系入手,认为本病初起在"枢",属气分;久病转入"阖",属血分,两个阶段可相互转化,与六经气化分别对应的"风""热""火""燥"相关.治疗上根据经络诊察确定经络虚实状态,将特定穴不同穴性配为"对穴",根据"枢机"气分及"内阖"血分分层治疗,并认为井穴放血不仅泻热,还具备祛瘀、引阳通络之功,为PSD的针灸治疗开辟了新思路.

1Guangdong Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine, Foshan, People’s Republic of China; 2The Fifth Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 3Guangdong Second Traditional Chinese Medicine Hospital, Guangzhou, People’s Republic of China; 4The Ninth People’s Hospital of Nanhai District, Foshan, People’s Republic of China

目的:观察夹脊电针联合Mulligan动态关节松动术治疗神经根型颈椎病的临床疗效.方法:选取2018年3月-2019年6月和田地区人民医院康复科和北京小汤山医院康复科门诊和病房神经根型颈椎病患者72例,根据随机对照分为对照组和治疗组各36例.两组患者均给予营养神经和消炎止痛治疗,对照组采用普通针刺和颈椎牵引和按摩治疗,治疗组采用夹脊电针和Mulligan动态关节松动术进行治疗,电针每天1次,以6 d为一个疗程,动态关节松动术每周2次,共治疗4个疗程,治疗前后并应用疼痛视觉模拟评分法(Visual Analogue Scale,VAS)评分表和颈椎活动度量表以及总共有效率评估疗效.结果:颈椎活动度(前屈、后伸、旋转)明显改善.组内比较:与治疗前相对比,治疗后两组患者的VAS评分均显著下降(P<0.01).组间比较:①疗前两组患者VAS评分和关节活动度比较,差异无统计学意义(P>0.05).②治疗后的VAS评分对比,治疗组显著低于对照(P<0.05);③两组患者治疗后总有效率比较,观察组治疗有效率为94.3％(33/35),与对照组(88.2％,30/34)比较差异有统计学意义(P<0.05).结论:夹脊电针联合Mulligan动态关节松动术治疗颈型颈椎病可明显改善患者颈椎活动度,从而缓解疼痛和麻木的症状.

OBJECTIVE:To compare the clinical efficacy differences between WANG Ju-yi 's meridian diagnosis method combined with Bobath rehabilitation training and Bobath rehabilitation training alone for post-stroke shoulder-hand syndrome (SHS) typeⅠ.METHODS:A total of 106 patients with post-stroke SHS typeⅠwere randomly divided into an observation group (53 cases, 2 cases dropped off ) and a control group (53 cases, 3 cases dropped off ). The patients in the both groups were treated with medications for basic diseases and conventional acupuncture at Waiguan (TE 5), Shousanli (LI 10) and Jianyu (LI 15) on the affected side. In addition, the patients in the control group were treated with Bobath rehabilitation training, 20 minutes each time; on the basis of the control group, the patients in the observation group were treated with WANG Ju-yi's meridian diagnosis method to adjust the abnormal parts in meridians of the hand taiyin and hand yangming on the affected side, 20 minutes each time. Both groups were treated once a day, 5 times a week for 8 weeks. The scores of visual analogue scale (VAS), upper-limb Fugl-Meyer assessment (FMA) and Barthel index (BI) were recorded before and after treatment as well as 6 weeks after treatment (follow-up), and the clinical efficacy of the two groups was evaluated after treatment.RESULTS:Compared before treatment, the VAS scores were reduced and the scores of upper-limb FMA and BI were increased in the two groups after treatment and in the follow-up (P<0.05). The VAS score in the observation group was lower than that in the control group (P<0.05), and the scores of upper-limb FMA and BI in the observation group were higher than those of the control group (P<0.05). The total effective rate in the observation group was 82.4% (42/51), which was higher than 62.0% (31/50) in the control group (P<0.05).CONCLUSION:WANG Ju-yi 's meridian diagnosis method combined with Bobath rehabilitation training could effectively treat post-stroke SHS typeⅠ, reduce pain symptoms and improve joint motor dysfunction, and improve the quality of life. Its curative effect is better than Bobath rehabilitation training alone.

目的 观察温通手功能治疗器对中风病手功能障碍的临床疗效.方法 收集2019年7月至2021年12月在北京小汤山医院康复中心住院的脑卒中(包括脑出血、脑梗死)患者56例,按照随机数字表法分为对照组28例与试验组28例.试验组予以常规康复治疗与改良温通手功能治疗器治疗,对照组仅予常规康复治疗,观察两组患者Fugl-Meyer评定量表(FMA)上肢功能动作评分、改良Ashworth评分(MAS)以及改良Barthel指数评定量表(MBI)等的变化.结果 治疗后,试验组患者FMA上肢功能动作评分、MBI评分明显高于对照组,差异具有统计学意义(均P<0.05);试验组患者的FMA上肢功能动作评分、MBI评分治疗前后差值均明显高于对照组,差异具有统计学意义(P<0.01,P<0.05);试验组患者的MAS分级较对照组显著降低,差异具有统计学意义(P<0.05).试验组治疗后MAS分级较治疗前显著降低,差异具有统计学意义(P<0.01).结论 温通手功能治疗器可降低中风患者患肢的肌张力分级,改善患肢痉挛程度以及手功能状态,提高日常生活活动能力.

Objective This study aims to evaluate the safety and efficacy of various levels of moxibustion smoke concentration (MSC), represented by particulate matter 10mm (PM10), on pain and motor dysfunction in patients with stage 1 post-stroke shoulder-hand syndrome (SHS). Materials and Methods In this multi-center, sham-controlled, single-blind, randomized controlled trial (RCT), a total of 140 eligible patients with stage 1 post-stroke SHS will be recruited from March 2022 to February 2023 and randomly allocated to five groups in a ratio of 1:1:1:1:1. Moxibustion, in addition to standard medical care, will be applied to subjects in all groups. No acupoints on the affected upper limb will be utilized. Moxibustion smoke therapy, with varying levels of MSC, will be applied to the five groups as follows: (A) sham control group, (B) zero MSC group, (C) low MSC group, (D) medium MSC group, and (E) high MSC group. Patients in each group will be treated for 20 minutes per session, with five sessions each week, over a course of six weeks, with a total follow-up interval of eight weeks. The primary outcome measure will be a visual analog scale (VAS) assessment of the intensity of regionalized pain in the affected upper limb. Secondary outcome measures will include scoring on the Fugl-Meyer Assessment of the Upper Extremity Scale (FMA-UE), the Modified Barthel Index (MBI) and the measurement of somatosensory evoked potential (SEP). All participants will be evaluated before treatment, during treatment (ie, at two weeks and four weeks), immediately after concluding treatment (ie, at six weeks) and at two weeks post-treatment (ie, at eight weeks). Intention-to-treat analysis will be applied. Trial Registration Number ChiCTR2100043076.

目的 探讨俞募配穴针刺法配合雷火灸治疗中风后尿失禁的临床疗效.方法 选取2017年10月～2020年10月我院收治的中风后尿失禁患者70例为研究对象,按照随机数字表法分成对照组(n=35)和观察组(n=35).对照组采用中风后尿失禁常规康复治疗,观察组在对照组基础上配合俞募配穴针刺及雷火灸治疗.比较两组患者尿失禁程度、排尿日记及临床疗效.结果 两组患者尿失禁程度均减轻,且观察组优于对照组,差异有统计学意义(P<0.05);两组日间排尿次数、夜间排尿次数、24 h尿失禁次数低于治疗前,单次排尿量高于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05);两组最大膀胱容量高于治疗前,残余尿量低于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05);观察组总有效率为90.91％,高于对照组的68.57％,差异有统计学意义(P<0.05).结论 俞募配穴针刺法结合雷火灸对改善中风后尿失禁程度,减少患者排尿及尿失禁次数疗效明确.

Background: Shoulder hand syndrome (SHS) is one of the common complications after a stroke, with the incidence rate up to 75% in China. The stage Ⅰ level is manifested as chronic pain and limitation of movement, which could cause irreversible muscle atrophy, joint deformation and even loss of motor function if progress to stage Ⅱ and Ⅲ. Auricular acupuncture, as one important component of traditional Chinese medicine (TCM) is a micro acupuncture therapy which combines acupuncture and holographic theory. However, the clinical efficacy of auricular acupuncture is still controversial and the length of improvement by auricular acupuncture has not been validated by clinical studies. Therefore, this study aims to evaluate the efficacy and duration of auricular acupuncture for pain relief and for motor function improvement in stage Ⅰ of SHS after ischemic stroke. Methods: This is a randomized, sham-controlled, patient-blinded trial. A total of 108 eligible patients with stage Ⅰ of SHS after ischemic stroke will be recruited from September 2018 to December 2020 and will be randomly allocated to three groups, A, B, or C, with a 1:1:1 ratio. Only body acupuncture will be applied in group A as a control group. Non-needle-insertion for sham auricular acupuncture will be combined with body acupuncture and applied to group B, whereas auricular acupuncture combined with body acupuncture will be applied in group C. Patients will be treated for 30 min per session, for 5 sessions per week for 3 weeks, and followed up for 6 weeks. The primary outcome will be the visual analog scale (VAS) for the shoulder and hand pain. The secondary outcomes will include the Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) and Modified Brathel Index (MBI). Eligible patients would be evaluated before treatment, immediately after treatment, and followed up after 1 week, 2 weeks and 6 weeks to verify the duration of auricular acupuncture effect. Discussion: This trial will help to identify the effectiveness and duration of auricular acupuncture effect for stage Ⅰ of SHS after ischemic stroke. Trial registration: www.chictr.org.cn, Chinese Clinical Trial Registry: ChiCTR2000037946. Retrospectively registered on 4 March 2020.

目的 观察艾灸联合针刺治疗缺血性卒中后肩手综合征(SHS)Ⅰ期的临床疗效.方法 选取2018年12月-2020年7月北京中医药大学附属护国寺中医医院针灸科及北京小汤山医院中西医结合康复科住院的120例缺血性率中后SHS Ⅰ期患者,采用随机数字表法分为对照组、无烟艾灸组和艾灸组,各40例.对照组采用常规体针治疗;无烟艾灸组在对照组治疗基础上加无烟艾灸治疗;艾灸组在对照组治疗基础上加正常艾灸治疗.3组治疗周期均为3周,结束后对比3组临床疗效,治疗前后及治疗后4周随访时视觉模拟评分(VAS)、上肢Fugl-Meyer评分(FMA)及Barthel指数(BI).结果 3组总有效率中艾灸组最高为85.7％,对照组最低为78.8％,但3组间差异无统计学意义(P＞0.05).治疗后各组VAS评分均较治疗前降低(P＜0.05),FMA及BI评分均较治疗前升高(P＜0.05);艾灸组治疗后BI及4周随访时VAS、FMA、BI评分与对照组、无烟艾灸组比较,差异均有统计学意义(P＜0.05).结论 艾灸联合针刺治疗可减轻缺血性卒中后SHS Ⅰ期患者疼痛,改善局部运动功能,提高生活质量.

井穴者阴阳之交,在王居易经络诊察体系中,不仅重视其可泻实清热,开窍祛瘀,更强调其引阳通络,行气导滞.王教授倡导井穴应用要在经络诊察基础上首辨病变经络虚实,后据辨经、选经原则,选取本经或表里经之井穴以达补泻之功;依据井穴新定位,采用指甲压押法及点刺放血辅助艾灸法为主要操作,根据经络虚实选择放血滴数,并配伍其他特定穴以提高临床疗效.